Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab
This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor-based therapy. A retrospective multicenter study (n =...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2024-03-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255 |
| _version_ | 1827317490700517376 |
|---|---|
| author | Hasan Cagri Yildirim Hicran Anik Deniz Ates Ozdemir Rashad Ismayilov Arif Akyildiz Kerim Cayiroz Fahri Ceyhan Oguzalp Kavruk Deniz Can Guven Ozturk Ates Alp Usubutun Zafer Arik |
| author_facet | Hasan Cagri Yildirim Hicran Anik Deniz Ates Ozdemir Rashad Ismayilov Arif Akyildiz Kerim Cayiroz Fahri Ceyhan Oguzalp Kavruk Deniz Can Guven Ozturk Ates Alp Usubutun Zafer Arik |
| author_sort | Hasan Cagri Yildirim |
| collection | DOAJ |
| description |
This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy.
|
| first_indexed | 2024-04-24T23:39:43Z |
| format | Article |
| id | doaj.art-0a6679b01dca4c8a82ddcef55b98579d |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:39:43Z |
| publishDate | 2024-03-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-0a6679b01dca4c8a82ddcef55b98579d2024-03-15T13:20:50ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2024-03-0110.17305/bb.2024.10255Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumabHasan Cagri Yildirim0https://orcid.org/0000-0003-3060-377XHicran Anik1https://orcid.org/0009-0001-7992-4008Deniz Ates Ozdemir2Rashad Ismayilov3https://orcid.org/0000-0002-7093-2722Arif Akyildiz4https://orcid.org/0000-0002-4452-2076Kerim Cayiroz5https://orcid.org/0009-0002-1063-7948Fahri Ceyhan6Oguzalp Kavruk7Deniz Can Guven8Ozturk Ates9https://orcid.org/0000-0003-0182-3933Alp Usubutun10Zafer Arik11Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, TurkeyDepartment of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital, Ankara, TurkeyDepartment of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor-based therapy. A retrospective multicenter study (n = 34) explored HIF-1 alpha expression via immunohistochemistry in patients treated with platinum chemotherapy and bevacizumab. Median progression-free survival (PFS) was significantly lower in the HIF-1 alpha low score group compared to the high score group (4.9 vs 12.9 months, P = 0.014). Similarly, the median overall survival (OS) was significantly reduced in the HIF-1 alpha low score group (8.3 vs 20.4 months, P = 0.006). This study, the first of its kind, highlights the prognostic significance of HIF-1 alpha expression in metastatic cervical SCC patients treated with bevacizumab-based therapy. https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255Metastatic cervical cancersquamous cell carcinoma (SCC)vascular endothelial growth factor (VEGF)hypoxia-inducible factor-1 alpha (HIF-1 alpha)bevacizumab |
| spellingShingle | Hasan Cagri Yildirim Hicran Anik Deniz Ates Ozdemir Rashad Ismayilov Arif Akyildiz Kerim Cayiroz Fahri Ceyhan Oguzalp Kavruk Deniz Can Guven Ozturk Ates Alp Usubutun Zafer Arik Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab Biomolecules & Biomedicine Metastatic cervical cancer squamous cell carcinoma (SCC) vascular endothelial growth factor (VEGF) hypoxia-inducible factor-1 alpha (HIF-1 alpha) bevacizumab |
| title | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
| title_full | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
| title_fullStr | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
| title_full_unstemmed | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
| title_short | Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab |
| title_sort | effect of hypoxia inducible factor 1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first line chemotherapy and bevacizumab |
| topic | Metastatic cervical cancer squamous cell carcinoma (SCC) vascular endothelial growth factor (VEGF) hypoxia-inducible factor-1 alpha (HIF-1 alpha) bevacizumab |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255 |
| work_keys_str_mv | AT hasancagriyildirim effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT hicrananik effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT denizatesozdemir effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT rashadismayilov effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT arifakyildiz effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT kerimcayiroz effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT fahriceyhan effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT oguzalpkavruk effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT denizcanguven effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT ozturkates effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT alpusubutun effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab AT zaferarik effectofhypoxiainduciblefactor1alphaexpressiononsurvivalinpatientswithmetastaticcervicalsquamouscellcarcinomatreatedwithfirstlinechemotherapyandbevacizumab |